Two Sigma Advisers
IOVA icon

Two Sigma Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

Two Sigma Advisers’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,015,000
Closed -$8.23M – 1057
2025
Q4 		$8.23M Buy
3,015,000
+1,956,000
+185% +$4.53M 0.02% 610
2025
Q3 		$2.3M Sell
1,059,000
-1,275,900
-55% -$3.01M ﹤0.01% 1078
2025
Q2 		$4.02M Buy
+2,334,900
New +$5.81M 0.01% 814
2023
Q3 		– Sell
-802,700
Closed -$5.65M – 2478
2023
Q2 		$5.65M Sell
802,700
-441,500
-35% -$3.16M 0.01% 710
2023
Q1 		$7.6M Buy
1,244,200
+396,800
+47% +$2.74M 0.02% 644
2022
Q4 		$5.41M Buy
847,400
+172,700
+26% +$1.35M 0.02% 752
2022
Q3 		$6.46M Buy
674,700
+491,600
+268% +$5.67M 0.02% 635
2022
Q2 		$2.02M Buy
183,100
+132,400
+261% +$1.74M 0.01% 1210
2022
Q1 		$844K Buy
50,700
+4,500
+10% +$69.6K ﹤0.01% 1727
2021
Q4 		$882K Buy
+46,200
New +$1.02M ﹤0.01% 1623
2021
Q2 		– Sell
-103,200
Closed -$3.27M – 2560
2021
Q1 		$3.27M Sell
103,200
-20,900
-17% -$866K 0.01% 1043
2020
Q4 		$5.76M Buy
124,100
+78,900
+175% +$3.13M 0.02% 766
2020
Q3 		$1.49M Buy
45,200
+7,500
+20% +$230K ﹤0.01% 1313
2020
Q2 		$1.03M Sell
37,700
-1,200
-3% -$39.5K ﹤0.01% 1563
2020
Q1 		$1.16M Sell
38,900
-61,900
-61% -$1.64M ﹤0.01% 1389
2019
Q4 		$2.79M Buy
100,800
+73,300
+267% +$1.67M 0.01% 1074
2019
Q3 		$501K Buy
+27,500
New +$608K ﹤0.01% 1710
2019
Q2 		– Sell
-51,400
Closed -$489K – 2373
2019
Q1 		$489K Sell
51,400
-36,600
-42% -$356K ﹤0.01% 1806
2018
Q4 		$779K Buy
+88,000
New +$849K ﹤0.01% 1594
2018
Q3 		– Sell
-19,800
Closed -$253K – 2305
2018
Q2 		$253K Buy
+19,800
New +$289K ﹤0.01% 2147

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Two Sigma Advisers's IOVA Position: Q1 2026 in Review

Two Sigma Advisers sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 3,015,000 shares — an estimated $8.23M sold.

Two Sigma Advisers first reported a position in IOVA in Q2 2018 and held it in 20 quarters. The position peaked at $8.23M in Q4 2025. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Two Sigma Advisers reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 3,015,000 Iovance Biotherapeutics shares in Q1 2026, an estimated $8.23M.
  • Two Sigma Advisers first reported a position in Iovance Biotherapeutics in Q2 2018 and held it in 20 quarters.
  • Two Sigma Advisers's Iovance Biotherapeutics position peaked at $8.23M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.